DoseEase for Users vs cubeTMFm Uso & Estadísticas

DoseEase manages and monitors the drug administration data of clinical trials on blockchain in real-time. Blockchain securely protects vital data from corruption, tampering, and losses, thus guaranteeing the Integrity of Clinical Trial data
  • App Store de Apple
  • Gratis
  • Salud y fitness

Clasificación de tiendas

- -

cubeTMFm is a mobile app developed to provide smartphone access to cubeTMF® web services — CRScube’s trial master file (TMF) management solution for clinical trials. App Features: - Access and download TMF documents. - eSign and QC documents per automated workflows. - Upload document files using PDFs or images. About the Web App: cubeTMF® is CRScube’s web application for paperless trial master file (TMF) management. cubeTMF is fully scalable and exists securely on the cloud for global centralized access. The system provides a simple, user-friendly interface and end-to-end features for constructing and managing a TMF repository as well as processing documents through automated eSign and QC workflows. CRScube: CRScube provides a comprehensive suite of eClinical solutions to CROs, Biotech, Pharmaceutical, Academic, and Non-Profit organizations globally. We are dedicated to providing the latest eClinical technology that is fast, flexible, and easy-to-use to streamline end-to-end operations for Phase I-IV, medical device, and Investigator-Initiated Trials.
  • App Store de Apple
  • Gratis
  • Medicina

Clasificación de tiendas

- -

DoseEase for Users frente a cubeTMFm: comparación de la clasificación

Comparar la tendencia de clasificación de DoseEase for Users en los últimos 28 días con cubeTMFm

Rank

No hay datos disponibles

Comparación de las clasificaciones DoseEase for Users frente a cubeTMFm por países

Comparar la tendencia de clasificación de DoseEase for Users en los últimos 28 días con cubeTMFm

No hay datos para mostrar

Compara con cualquier sitio gracias a nuestra prueba gratuita

Empieza ya
DoseEase for Users VS.
cubeTMFm

19iciembre d, 2024